Cancer Biomarkers Market Size, Share, Growth, Trends, and Forecast 2030

Table Of Content

Methodology

Free Analysis

Cancer biomarkers are molecules which are released in the presence of a tumor or show a particular indication in the body related to the presence of cancer. These are molecular substances or a physical condition that shows the presence of cancer cells in the body. These kinds of molecules are usually found in the urine, tissues, blood, serum, and other body fluids. Cancer biomarkers are noticeable substances that can be utilized as a sign of biological state for tumor, therefore it can be utilized to prognostic stages of cancer and analyze test as well.

The global cancer biomarkers market is segmented as biomarker type, cancer type, profiling technology, applications, and by geography. Based on biomarker type, the global cancer biomarkers market is segmented as genetic biomarkers, protein biomarkers, and other biomarkers. Based on cancer type, the market is segmented as breast cancer, colorectal cancer, lung cancer, prostate cancer, blood cancer, melanoma, ovarian cancer, liver cancer, stomach cancer, and other cancer types. By profiling technology, the cancer market is further segmented as imaging technologies, omic technologies, cytogenetics-based tests, and immunoassays. The omic technologies segment is further segmented as genomics, proteomics, and other omic technologies. Based on applications, the cancer biomarkers market is segmented as drug discovery and development, personalized medicine, diagnostics, and other applications.

By geography, the global cancer biomarkers market is segmented into North America, Europe, Latin America, Asia Pacific, and the Middle East & Africa. North America dominated the cancer biomarkers market globally in 2017 and is expected to remain dominant over the forecast period. The high prevalence of cancer, large demand for technically advanced diagnostics for cancer, high government support for diagnostics and treatment of chronic diseases are the key factor contributing towards the high share of North America in the global cancer biomarkers market. In terms of growth rate, Asia Pacific is anticipated to register high growth in the global cancer biomarkers market. The growing government support to avail advanced diagnostics tools and large patient pool, are the main factors expected to propel the growth of the cancer biomarkers market in the region. 

Some of the key players in the cancer biomarkers market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Agilent Technologies, QIAGEN, Illumina, Inc., QIAGEN, Sino Biological Inc., Merck & Co., Inc., Novartis AG, Hologic, Inc., bioMérieux SA, Genomic Health, Inc., among others. The increasing investment by the key players in research and development activities to enhance the product portfolio is expected to propel the growth of the cancer biomarkers market in the coming future. For instance, in November 2016, the Thermo Fisher Scientific announced four new additions to its product portfolio for cancer research of multi-biomarker targeted assays. The new development includes the Oncomine Immune Response Research Assay, which is designed to cross-examine microenvironment of the tumor and allow identification of prognostic biomarkers for immunotherapy clinical research trials.